T.gondii MIC-3

Toxoplasma Gondii MIC 3 Recombinant

The E.Coli derived recombinant protein contains the MIC3 immunodominant regions, amino acids 234-306. MIC3 protein is fused to a 26Kda Glutathione transferase tag.
Shipped with Ice Packs
Cat. No.
BT7222
Source
Escherichia Coli.
Appearance

T.gondii p24

Toxoplasma Gondii p24 (GRA1) Recombinant

The E.Coli derived recombinant protein contains the p24 (GRA1) immunodominant regions, fused to six histidines at C-terminal. 

Shipped with Ice Packs
Cat. No.
BT7309
Source
Escherichia Coli.
Appearance

T.gondii p29

Toxoplasma Gondii p29 (GRA7) Recombinant

The E.coli derived recombinant protein contains the p29 (GRA7) immunodominant regions, amino acids 24-100 and fused to a 26kDa GST tag.
Shipped with Ice Packs
Cat. No.
BT7384
Source
Escherichia Coli.
Appearance

T.gondii p30

Toxoplasma Gondii p30 (SAG1) Recombinant

T.gondii p30 is highly conformational antigen containing 12 cysteine residues and is fused to a 6 x His tag at its C-terminus.

Shipped with Ice Packs
Cat. No.
BT7469
Source
Escherichia Coli.
Appearance

T.gondii p40

Toxoplasma Gondii p40 Recombinant

The E.Coli derived recombinant Toxoplasma Gondii p40 having a Mw of 35kDa and fused to a 6 His tag at C-terminus can be used to test the specific IgG and IgM antibody for the diagnosis of Toxoplasma gondii infection.
Shipped with Ice Packs
Cat. No.
BT7938
Source
Escherichia Coli.
Appearance
Sterile Filtered clear solution.

T.gondii ROP4

Toxoplasma Gondii ROP4 (RH2) Mosaic Recombinant

The E.coli derived recombinant artificial mosaic protein contains the ROP4 (RH2) immunodominant regions, the protein is fused to Glutathione transferase.
Shipped with Ice Packs
Cat. No.
BT8014
Source
Escherichia Coli.
Appearance

Toxoplasma P22

Toxoplasma Gondii P22 (SAG2) Recombinant

Recombinant Toxoplasma Gondii P22 (SAG2) produced in E.coli is a full length Surface antigen 2 (SAG2) and fused with a 6xHis tag at C- terminus.
Shipped with Ice Packs
Cat. No.
BT8102
Source
Escherichia Coli.
Appearance
Sterile Filtered solution.

Toxoplasma P32

Toxoplasma Gondii P32 (GRA6) Recombinant

Recombinant Toxoplasma Gondii P32 (GRA6) produced in E.coli containing 180 amino acids of the Dense Granule Antigen 6 (GRA6) and fused with a 6xHis tag at C- terminus. This antigen forms dimers on SDS-PAGE under denatured conditions, compared to other toxoplasma monomer antigens, it has better immunoreactions.
Shipped with Ice Packs
Cat. No.
BT8180
Source
Escherichia Coli.
Appearance
Sterile Filtered solution.

Toxoplasma P35

Toxoplasma Gondii P35 (GRA8) Recombinant

Recombinant Toxoplasma Gondii P35 (GRA8) containing 217 amino acids was purified from E. coli.
The Recombinant Toxoplasma Gondii P35 (GRA8) is fused to GST tag at its N terminal and purified by proprietary chromatographic technique.

Shipped with Ice Packs
Cat. No.
BT8252
Source

Escherichia Coli.

Appearance

Sterile Filtered clear solution.

Definition and Classification

Toxoplasma gondii is a parasitic protozoan belonging to the phylum Apicomplexa. It is the causative agent of toxoplasmosis, a disease that can infect most warm-blooded animals, including humans. The definitive hosts for T. gondii are members of the family Felidae (domestic cats and their relatives), where the parasite undergoes sexual reproduction .

Biological Properties

Key Biological Properties: T. gondii is an obligate intracellular parasite, meaning it must live within a host cell to survive. It exists in three forms: tachyzoites, bradyzoites, and oocysts . Tachyzoites are the rapidly multiplying form seen during acute infection, while bradyzoites are found within tissue cysts during chronic infection. Oocysts are shed in the feces of infected cats and are the form that can infect new hosts .

Expression Patterns and Tissue Distribution: T. gondii can infect a wide range of tissues, including neural and muscular tissues, such as the brain, eyes, and skeletal and cardiac muscles . The parasite’s ability to persist in the central nervous system (CNS) is particularly notable .

Biological Functions

Primary Biological Functions: T. gondii’s primary function is to replicate and spread within its host. It achieves this by invading host cells and forming a parasitophorous vacuole, where it can replicate safely .

Role in Immune Responses and Pathogen Recognition: T. gondii can modulate the host’s immune response to facilitate its survival. It can evade the host’s immune system by altering the expression of immune-related genes and proteins . The parasite’s ability to persist in the CNS and other tissues is partly due to its ability to evade immune detection .

Modes of Action

Mechanisms with Other Molecules and Cells: T. gondii interacts with host cells through various mechanisms. It can manipulate the host cell’s cytoskeleton and signaling pathways to facilitate its entry and replication . The parasite’s surface proteins and secreted effectors play crucial roles in these interactions .

Binding Partners and Downstream Signaling Cascades: T. gondii’s surface proteins, such as microneme and rhoptry proteins, are involved in the initial attachment and invasion of host cells . Once inside the host cell, the parasite can manipulate various signaling pathways to promote its survival and replication .

Regulatory Mechanisms

Regulatory Mechanisms Controlling Expression and Activity: T. gondii’s gene expression is tightly regulated to adapt to different stages of its life cycle. Transcriptional regulation involves various transcription factors and epigenetic modifications . Post-translational modifications, such as phosphorylation, also play a role in regulating the activity of parasite proteins .

Transcriptional Regulation and Post-Translational Modifications: The parasite’s ability to switch between tachyzoite and bradyzoite forms is controlled by a complex network of transcriptional regulators and epigenetic modifications . These regulatory mechanisms ensure that the parasite can adapt to different host environments and stages of infection .

Applications in Biomedical Research

Diagnostic Tools: T. gondii infection can be diagnosed through serological tests that detect specific antibodies or through molecular methods such as polymerase chain reaction (PCR) to detect parasite DNA . Advances in nanotechnology have also led to the development of novel diagnostic tools for toxoplasmosis .

Therapeutic Strategies: Current treatments for toxoplasmosis include antiparasitic drugs such as pyrimethamine and sulfadiazine . Research is ongoing to develop more effective and less toxic treatments, including peptide-based drugs and nanomedicine approaches .

Role in the Life Cycle

Role Throughout the Life Cycle: T. gondii has a complex life cycle involving both sexual and asexual reproduction. In the definitive host (cats), the parasite undergoes sexual reproduction to produce oocysts, which are shed in the feces . Intermediate hosts, including humans, become infected by ingesting oocysts or tissue cysts . Within the intermediate host, the parasite can switch between tachyzoite and bradyzoite forms, allowing it to persist for the host’s lifetime .

From Development to Aging and Disease: T. gondii infection can have various effects on the host, depending on the host’s immune status and the stage of infection. In immunocompetent individuals, the infection is often asymptomatic or causes mild flu-like symptoms . However, in immunocompromised individuals or during congenital infection, T. gondii can cause severe disease, including encephalitis and congenital abnormalities .

© Copyright 2024 Thebiotek. All Rights Reserved.